ArticleScientific reports2025
SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chordomas are rare, aggressive tumors of the axial skeleton with limited treatment options. Genetic alterations in SMARCB1, a tumor suppressor gene, have been implicated in poorly differentiated chordomas, but their role in typical and chondroid subtypes remains unclear. This study examined 42 chordoma samples (26 typical, 16 chondroid) for SMARCB1 genetic alterations, expression patterns, and associated pathways. SMARCB1 knockdown experiments were conducted in chordoma cell lines, followed by comprehensive transcriptome analysis. No exonic SMARCB1 mutations were identified, but heterozygous loss was observed in 3/26 typical chordomas. SMARCB1 expression positively correlated with patient survival and epithelial-mesenchymal markers. Functional studies revealed that SMARCB1 knockdown significantly enhanced cell proliferation, migration, and invasion. Transcriptome analysis demonstrated enrichment of MYC targets, E2F targets, and cell cycle pathways in SMARCB1-low samples, while cellular adhesion pathways were downregulated. Notably, SLPI, LBH, and LOXL2 were significantly downregulated in SMARCB1-low samples. SMARCB1 plays an important role in chordoma progression, influencing prognosis and cellular behavior, despite infrequent genetic alterations. Its effects on key oncogenic pathways and cellular plasticity suggest potential for targeted therapies. These findings provide new insights into chordoma biology and lay the groundwork for developing SMARCB1-based prognostic tools and personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.